Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia (MultiCov)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04334850
Recruitment Status : Recruiting
First Posted : April 6, 2020
Last Update Posted : May 27, 2020
Sponsor:
Collaborator:
BioMérieux
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

The novel coronavirus SARS-CoV-2 (COVID-19) is an emerging respiratory virus that causes pneumonia. WHO data reported admission to the intensive care unit (ICU) for 6% of patients, with a mortality rate reaching 45%. To date, apart from therapeutic trials, ICU management is symptomatic, based on organ failure support therapies. In the initial phase, the therapeutic management also includes empiric antimicrobial therapy (90% of patients, in accordance with LRTI guidelines (ATS 2019) and SRLF Guidelines (2020). One challenge for the ICU physicians is the timing for discontinuation of antimicrobial treatment, especially in case of shock or ARDS, considering that a substantial proportion of COVID-19 pneumonia patients may have pulmonary bacterial coinfection/superinfection. In order to avoid unnecessary prolonged antimicrobial therapy, and subsequent selective pressure, two tests could be combined in a personalized antibiotic strategy:

  • Procalcitonin (PCT): PCT is a useful tool to guide antibiotics discontinuation in community-acquired pneumonia) and viral pneumonia (PMID24612487).
  • Respiratory multiplex PCR FA-PPP (Biomérieux®): panel has been enlarged, including 8 viruses and 18 bacteria (quantitative analysis). The turnaround time is short. Sensitivity is high (99%, PMID32179139). It may contribute, in combination with conventional tests, to accelerate and improve the microbiological diagnosis during severe COVID-19 pneumonia.

The hypothesize of the study is that the combination of the mPCR FA-PPP and PCT could be used to reduce antibiotics exposure in patients with severe confirmed COVID-19 pneumonia, with a higher clinical efficacy and safety as compared with a conventional strategy.


Condition or disease Intervention/treatment Phase
Covid19 Pneumonia Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin Other: Usual antibiotic treatment Not Applicable

Detailed Description:

Inclusion (D0_H0) is performed in ICU as soon as possible, once the diagnosis of COVID-19 pneumonia is confirmed. Therefore, inclusion might be performed either on ICU admission (if the COVID-19 pneumonia has been confirmed in the pre-ICU wards) or during the ICU stay (if the COVID-19 pneumonia was confirmed after ICU admission). Conventional microbiological investigations are left at the discretion of the physicians, and may include blood cultures, Streptococcus pneumoniae and Legionella pneumophila urinary antigen assays, and a respiratory tract sample for Gram stain examination and 2 days-long culture (if not already done in the past 24 hours). Usual biology includes procalcitonin measurement. Empirical antimicrobial therapy combines a third-generation cephalosporin and a macrolide, or broader-spectrum antibiotics if risk factors for resistant bacteria are identified.

Randomization is performed immediately after the inclusion.

  • In the intervention arm, a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
  • In the control arm, the antimicrobial therapy is left at the discretion of the physicians, as in usual practice.

Evaluation criteria are collected at hospital discharge or at D28, and D90. The vital status may be obtained by phone call at D28 (if the patient has been discharged before D28) and at D90.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 194 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial
Actual Study Start Date : April 20, 2020
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : August 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Targeted antibiotic treatment according to the results of mPCR
a broad panel respiratory Mpcr FA-PPP is performed on respiratory tract sample (tracheal aspirate, BAL or sputum), collected 12 hours after inclusion. An algorithm of early antibiotic adaptation and discontinuation, based on the microbiological results, including the mPCR FA-PPP results, and the procalcitonin values and kinetics will be used. This algorithm will be applied as soon as possible after inclusion, and repeated day after day until D7.
Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin
The actions or procedures added by the research are the application of the algorithm of early antibiotics de-escalation and discontinuation.

Control arm
The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.
Other: Usual antibiotic treatment
The antimicrobial therapy is left at the discretion of the physicians, as in usual practice.




Primary Outcome Measures :
  1. Number of antibiotic free days [ Time Frame: Day 28 ]
    the number of days alive without any antibiotics at Day 28. The D28 time point is usual in studies assessing antibiotics saving in ICU patients.


Secondary Outcome Measures :
  1. Mortality rates [ Time Frame: Day 28 and Day 90 ]
  2. Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics. [ Time Frame: day 28 ]
  3. Antibiotics duration at D28 [ Time Frame: Day 28 ]
    Total exposure to antibiotics

  4. Number of organ-failure free days (based on SOFA) [ Time Frame: Day 28 ]
  5. Incidence rates of bacterial super-infections [ Time Frame: day 28 ]
  6. Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections [ Time Frame: Day 28 ]
  7. ICU and hospital lengths of stay [ Time Frame: Day 28 ]
  8. Quality of life Quality of life [ Time Frame: Day 90 ]
    using a quality of life questionnaire (EQ5D5L)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults (>= 18 years) admitted to the ICU;
  • Severe confirmed COVID-19 pneumonia, defined by i) a newly-appeared pulmonary parenchymal infiltrate; and ii) a positive RT-PCR (either upper or lower respiratory tract) for COVID-19 (SARS-CoV-2); iii) and admission to the ICU or intermediate care unit;
  • Informed consent or emergency procedure.

Exclusion Criteria:

  • Pregnancy ;
  • Congenital immunodeficiency;
  • HIV infection with CD4 count below 200/mm3 or unknown in the last year;
  • High-grade hematological malignancy;
  • Neutropenia (<1 leucocyte/mL or < 0.5 neutrophil/mL);
  • Immunosuppressive drugs within the previous 30 days, including anti-cancer cytotoxic chemotherapy and anti-rejection drugs for organ/bone marrow transplant;
  • Moribund patient or death expected from underlying disease during the current admission;
  • Patient deprived of liberty or under legal protection measure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04334850


Contacts
Layout table for location contacts
Contact: Muriel FARTOUKH, PU-PH MD PHD 01 56 01 65 74 muriel.fartoukh@aphp.fr
Contact: Guillaume VOIRIOT, MD 01 56 01 65 74 guillaume.voiriot@aphp.fr

Locations
Layout table for location information
France
Intensive care department-Hospital Tenon Recruiting
Paris, France, 75020
Contact: Muriel FARTOUKH, PU-PH MD PHD    01 56 01 65 74    muriel.fartoukh@aphp.fr   
Contact: Guillaume VOIRIOT, MD    01 56 01 65 74    guillaume.voiriot@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
BioMérieux
Investigators
Layout table for investigator information
Principal Investigator: Muriel FARTOUKH, PU-PH MD PHD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04334850    
Other Study ID Numbers: APHP200392
2020-001324-33 ( EudraCT Number )
First Posted: April 6, 2020    Key Record Dates
Last Update Posted: May 27, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
COVID-19 pneumonia
respiratory multiplex PCR
Procalcitonin
Antibiotics saving
Diagnosis
Treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Bacterial Agents
Anti-Infective Agents